Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Financials

Drugs Made In America Acquisition II Corp. (DMII)

NGM · Shell Companies

$10.11+0.01 (+0.05%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$644.0M
P/E (TTM)
77.77
EPS
$0.13
Div Yield
52W Range
$9.86–$10.20
Beta

Company overview

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.

Peers in Shell Companies

All in industry →

Recent press releases

Drugs Made In America Acquisition II Corp. has not issued a press release in this window.

SEC filings

All filings →

Drugs Made In America Acquisition II Corp. has not filed an SEC document in this window.

Drugs Made In America Acquisition II Corp. has no reported insider trades in the last 90 days.

Institutional holders

All holders →

No 13F holdings have been reported for Drugs Made In America Acquisition II Corp. in this window.

People at Drugs Made In America Acquisition II Corp.

All people →

Quarterly financials

Full financials →

No quarterly financials have been ingested for Drugs Made In America Acquisition II Corp..